Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma

Glioblastoma, a cancer that originates from astrocytes, is the most prevalent malignant glioma in the adult population. The aim of the present study was to evaluate the cost-effectiveness of bevacizumab (BEV) as a supplement to standard temozolomide (TMZ) treatment for unresected glioblastoma. The a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhaoyan, Zhan, Mei, Tian, Fangyuan, Xu, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924092/
https://www.ncbi.nlm.nih.gov/pubmed/31897155
http://dx.doi.org/10.3892/ol.2019.11099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924092/
https://www.ncbi.nlm.nih.gov/pubmed/31897155
http://dx.doi.org/10.3892/ol.2019.11099

Ejemplares similares